Pharma BD Deal Intelligence
A pivot disguised as a license: Cue Biopharma paid only $15M upfront for Ascendant-221 (up to $691.5M total), betting its allergy future on a China CSU readout still pending in 2H 2026 before the Phase 2b food-allergy trial can even start.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ascendant-221 is a humanized anti-IgE IgG1 monoclonal antibody that has a dual mechanism of action; it neutralizes free IgE with picomolar potency and…
Cue Biopharma announced today that it has entered into an exclusive license agreement with Ascendant Health Sciences Ltd. to develop, manufacture and…
Cue Biopharma's Q1 2026 results: collaboration revenue $5.7M (vs $0.4M YoY), net loss $5.2M (vs $12.3M), cash $16.4M at 3/31/2026; subsequent to quarter-end…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Cue Biopharma (CUE) entered an exclusive global (ex-Greater China) license from Ascendant Health Sciences for Phase 2-stage anti-IgE antibody Ascendant-221 for $15M upfront plus up to $676.5M in development/regulatory/commercial milestones plus tiered royalties. Cue plans to initiate a global Phase 2b food-allergy trial after the China CSU readout in 2H 2026. UPDATE (Q1 2026 reporting): Cue has redesignated the in-licensed asset CUE-221 (formerly Ascendant-221); the China CSU Phase 2 readout remains expected in 2H 2026 and the global food-allergy Phase 2b remains gated on that data. Cue reported $16.4M cash at 3/31/2026 plus a subsequent $30M private placement and a $7.5M milestone receipt, funding milestones into 2026.
32M US cases/yr · $8.5B US Market · 6.2% US adult food allergy prevalence (CDC)
IgE-mediated food allergy is a hypersensitivity reaction in which exposure to specific food proteins triggers mast-cell and basophil degranulation, producing symptoms ranging from urticaria and gastrointestinal distress to life-threatening anaphylaxis. The CDC estimates that approximately 6.2% of US adults and a comparable proportion of children carry a diagnosed food allergy, with peanut, tree nut, milk, egg, wheat, soy, fish, shellfish, and sesame accounting for the majority of severe reactions. Total US prevalence exceeds 32 million people. Until recently, management was almost entirely avoidance plus rescue epinephrine, with no disease-modifying option to raise reaction thresholds across multiple allergens simultaneously. Aimmune's Palforzia (peanut oral immunotherapy) gained FDA approval in 2020 but has experienced limited uptake due to demanding administration logistics and tolerability burdens. Xolair (omalizumab) won an FDA expanded indication in February 2024 for IgE-mediated food allergies in patients aged 1 and older, becoming the first systemic biologic for this population and validating the anti-IgE mechanism as a multi-allergen therapeutic strategy. The market is estimated at $7.6 billion in 2025 growing to $8.5 billion in 2026 with a 12% CAGR, with epinephrine devices currently capturing the largest share but biologics expected to drive the next phase of growth.
Food allergy therapeutics is a young, rapidly forming market. Xolair's February 2024 FDA label expansion to IgE-mediated food allergy ages 1+ established anti-IgE biologics as the leading systemic mechanism, eclipsing single-allergen oral immunotherapy approaches like Aimmune's Palforzia. Cue's Ascendant-221 enters the food allergy space as the most clinically advanced next-generation anti-IgE candidate, differentiated by its dual neutralization-plus-suppression mechanism and durable IgE knockdown profile. Cue plans to initiate a global Phase 2b food allergy trial after the China CSU readout in 2H 2026, putting it on a clinical timeline behind Xolair but with potential for less frequent dosing and broader free-IgE control. Adjacent biologic competitors in earlier development include depemokimab (anti-IL-5, GSK) and other Th2-pathway agents. The commercial unlock will hinge on demonstrating multi-allergen threshold elevation in placebo-controlled trials and pricing competitively against Xolair's existing access infrastructure.
1.6M US cases/yr · $2.0B US Market · ~50% Antihistamine-refractory rate
Chronic spontaneous urticaria (CSU) is a debilitating immunologic skin disorder defined by the recurrent appearance of itchy hives, angioedema, or both, lasting at least six weeks without an identifiable trigger. The condition is mediated by mast cell and basophil activation, with IgE autoantibodies against autoantigens such as thyroperoxidase (Type IIb autoimmunity) and IgG autoantibodies against the IgE receptor FcepsilonRI driving chronic histamine release. CSU disproportionately affects women in the third to fifth decades of life and substantially erodes sleep, work productivity, and mental health, with depression and anxiety prevalence two to three times that of the general population. Standard of care begins with second-generation H1-antihistamines at up to four times the licensed dose; roughly half of patients fail to achieve disease control on antihistamines alone. Refractory patients have historically been treated with omalizumab (Xolair), an anti-IgE monoclonal antibody, but approximately 30-40% achieve only partial response and another subset relapses on therapy. The therapeutic landscape expanded sharply in 2025 with FDA approval of dupilumab (anti-IL-4Ralpha) and Novartis's oral BTK inhibitor Rhapsido (remibrutinib) for antihistamine-refractory CSU, signaling a shift toward mechanistically diverse, biologically targeted regimens for this immune-mediated disease.
Omalizumab (Xolair, Genentech/Novartis) anchored the antihistamine-refractory CSU market for over a decade, but ~30-40% of patients still fail to achieve full disease control. The 2025 wave of approvals reshaped the field: Sanofi/Regeneron's dupilumab (Dupixent) won FDA approval in CSU in early 2025, and Novartis's oral BTK inhibitor Rhapsido (remibrutinib) cleared FDA on September 30, 2025 as the first targeted oral therapy. Ascendant-221 enters as a next-generation anti-IgE differentiated by its dual mechanism: picomolar free-IgE neutralization plus CD23-mediated suppression of new IgE synthesis, generating durable IgE knockdown for >12 weeks after a single Phase 1 dose. The China Phase 2 dose-ranging study in CSU includes an active omalizumab comparator arm, with readout in 2H 2026 the gating event for Cue's global Phase 2b food-allergy expansion. Differentiation-on-durability and dosing convenience versus omalizumab is the key commercial thesis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cue Biopharma, Inc. / Ascendant Health Sciences Ltd. (Ascendant-221) (this deal) | 2026 | $692M | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
← Browse all deals · How we score deals
More: 2026 deals · Immunology deals